Results 211 to 220 of about 73,286 (248)
American Journal of Obstetrics and Gynecology, 2019 BACKGROUND: The recent demonstration of a vaginal biofilm in bacterial vaginosis and its postulated importance in the pathogenesis of recurrent bacterial vaginosis, including relative resistance to therapy, has led to the hypothesis that biofilms are ...
Alexander Tertychnyy +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Phytomedicine
BACKGROUND Vulvovaginal candidiasis (VVC) is a common infection that affects the female reproductive tract. Pulsatilla decoction (PD), a traditional Chinese herbal medicine, is a classic and effective prescription for VVC.
Kaifan Hu +7 more
semanticscholar +1 more source
BACKGROUND Vulvovaginal candidiasis (VVC) is a common infection that affects the female reproductive tract. Pulsatilla decoction (PD), a traditional Chinese herbal medicine, is a classic and effective prescription for VVC.
Kaifan Hu +7 more
semanticscholar +1 more source
Mycoses (Berlin)
Recurrent vulvovaginal candidiasis (RVVC) is an important and underestimated fungal infection.
Jeiser Marcelo Consuegra-Asprilla +4 more
semanticscholar +1 more source
Recurrent vulvovaginal candidiasis (RVVC) is an important and underestimated fungal infection.
Jeiser Marcelo Consuegra-Asprilla +4 more
semanticscholar +1 more source
InnovAiT: Education and inspiration for general practice, 2013
Vulvovaginal candidiasis is a common condition that will, at some point, affect three-quarters of all women of reproductive age. It is caused by an overgrowth of Candida yeast. There are a number of situations that make candidiasis more likely, including pregnancy, diabetes, immunosuppression and use of antibiotics.
Adam Brocklebank, Hemant Maraj
openaire +1 more source
Vulvovaginal candidiasis is a common condition that will, at some point, affect three-quarters of all women of reproductive age. It is caused by an overgrowth of Candida yeast. There are a number of situations that make candidiasis more likely, including pregnancy, diabetes, immunosuppression and use of antibiotics.
Adam Brocklebank, Hemant Maraj
openaire +1 more source
Colloids and Surfaces B: Biointerfaces
Vulvovaginal candidiasis, mostly caused by Candida albicans, remains a prevalent concern in women's health. Annona muricata L. (Annonaceae), a plant native from Brazil, is well-known for its therapeutic potential, including antitumor, anti-inflammatory ...
L. M. Campos +10 more
semanticscholar +1 more source
Vulvovaginal candidiasis, mostly caused by Candida albicans, remains a prevalent concern in women's health. Annona muricata L. (Annonaceae), a plant native from Brazil, is well-known for its therapeutic potential, including antitumor, anti-inflammatory ...
L. M. Campos +10 more
semanticscholar +1 more source
Ibrexafungerp for the treatment of vulvovaginal candidiasis
Drugs of Today, 2022Worldwide, effective management of vulvovaginal candidiasis (VVC) continues to serve as a major therapeutic goal with numerous unmet drug treatment challenges. After 3 decades of azole drug dominance, with few recent new antifungal agents and little progress in VVC management, the first-in-class oral triterpenoid glucan synthase inhibitor agent ...
openaire +2 more sources
A serologic test for vulvovaginal candidiasis
International Journal of Gynecology & Obstetrics, 2003Vulvovaginal candidiasis (VVC) is a common medical problem affecting many women in the community w1–3x. The diagnosis of VVC remains problematic. Clinical features of VVC are nonspecific, and the standard laboratory test to identify Candida organisms from a vaginal swab may take between 5 to 7 days to confirm the diagnosis. Thus, as many as half of the
S W, Tan, A, Mackay, J, Warmington
openaire +2 more sources
Vulvovaginal Candidiasis: Treatment and Recurrence
Australian and New Zealand Journal of Obstetrics and Gynaecology, 1982Summary: This study compares the effectiveness of 6 treatment regimens for vulvovaginal candidiasis with 6 months' follow‐up. 292 patients randomly allocated to the treatments completed the trial. Significant differences were found in the rates of recurrence within the different treatment groups.
G J, Dennerstein, R, Langley
openaire +2 more sources
Clinical evidence, 2005
Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. Candida albicans accounts for 85% to 90% of cases.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic ...
openaire +5 more sources
Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. Candida albicans accounts for 85% to 90% of cases.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic ...
openaire +5 more sources
Pathogenesis of recurrent vulvovaginal candidiasis
Current Infectious Disease Reports, 2002Recurrent vulvovaginal candidiasis (RVVC) is by no means uncommon and is a source of considerable physical suffering, in addition to serving as a major therapeutic challenge. The syndrome is multifactorial in etiology, hence management strategies must recognize the complex etiologic pathways. Considerable progress has been made in identifying secondary
openaire +2 more sources